



ASX ANNOUNCEMENT

8 SEPTEMBER 2022

DR STEPHANIE H. ASTROW APPOINTED AS VICE PRESIDENT, TRANSLATIONAL SCIENCES

Chimeric Therapeutics (ASX: CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Dr Stephanie H. Astrow to the position of Vice President, Translational Sciences.

Dr Astrow joins Chimeric with more than 20 years of experience working in cell therapy and biotechnology.

At both Kite Pharma and Fate Therapeutics, she led the translational development programs for CAR T, TCR, and NK cell therapies, overseeing teams focused on the mechanistic understanding of engineered cell therapy products. At Kite, Dr Astrow was responsible for the solid tumor programs, including strategic collaborations with the National Cancer Institute.

Prior to her work in adoptive cell therapy, Dr Astrow was Vice President of Research and Development at Response Genetics, where she was responsible for novel oncology biomarker assay development.

She participated in the approvals of numerous clinical assays, including molecular and companion diagnostics used in cancer therapy selection. Prior to Response Genetics, she held leadership positions at Quest Diagnostics, Pathway Diagnostics, and Impath, Inc.

Dr Astrow holds a Bachelor of Arts in Biology and Medicine from Brown University, and earned her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She also holds a Masters of Business Administration from Pepperdine University.

She is an inventor on several patents and has published papers in the fields of oncology therapy and diagnostics development, among others.

Chimeric CEO & Managing Director Jennifer said: “Dr Astrow has extensive experience in the development of translational strategies for solid tumor and hematologic malignancies for adoptive cell therapies in both autologous and allogeneic settings. She will be a valuable addition to the Chimeric team as we continue to advance our deep clinical pipeline.”

Chimeric Chief Medical Officer Dr Jason B. Litten said: “This is a critical role on our team and Dr Astrow is a great scientist with deep cell therapy experience.”

For personal use only



ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in metastatic melanoma with future expansion to additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

For personal use only



CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

For personal use only